PUBLISHER: TechNavio | PRODUCT CODE: 1756541
PUBLISHER: TechNavio | PRODUCT CODE: 1756541
The gastrointestinal diseases therapeutics market is forecasted to grow by USD 20,683.2 mn during 2024-2029, accelerating at a CAGR of 7.1% during the forecast period. The report on the gastrointestinal diseases therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by increasing incidence of gastrointestinal diseases, new gastrointestinal therapeutics product approvals, and increasing demand for biologics and targeted therapies.
Market Scope | |
---|---|
Base Year | 2025 |
End Year | 2029 |
Series Year | 2025-2029 |
Growth Momentum | Accelerate |
YOY 2025 | 6.5% |
CAGR | 7.1% |
Incremental Value | $20,683.2 mn |
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.
Technavio's gastrointestinal diseases therapeutics market is segmented as below:
By Drug Class
By Type
By Route Of Administration
By Geographical Landscape
This study identifies the availability of nutritional therapies as one of the prime reasons driving the gastrointestinal diseases therapeutics market growth during the next few years. Also, emergence of microbiome-based therapies and increase in self-medication coupled with home-based therapies will lead to sizable demand in the market.
The report on the gastrointestinal diseases therapeutics market covers the following areas:
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading gastrointestinal diseases therapeutics market vendors that include Abbott Laboratories, AbbVie Inc., AstraZeneca Plc, Bayer AG, Biogen Inc., Boehringer Ingelheim International GmbH, Boston Scientific Corp., Eisai Co. Ltd., Eli Lilly and Co., Evoke Pharma Inc., GlaxoSmithKline Plc, Johnson and Johnson Services Inc., Merck and Co. Inc., Novartis AG, Olympus Corp., Ovesco Endoscopy AG, Pfizer Inc., Salix Pharmaceuticals Inc., Takeda Pharmaceutical Co. Ltd., and UCB SA. Also, the gastrointestinal diseases therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.
Exhibits: